Heron shares fly up after FDA (finally) approves its drug to rein in chemo side effects
Shares of Redwood City, CA-based Heron Therapeutics $HRTX shot up 20% on Wednesday morning after the biotech announced that the FDA has at long last approved its sustained-release formulation of Sustol (granisetron) to prevent nausea and vomiting for patients on chemo. The approval comes after a 6-year regulatory odyssey for Heron, which started with the first of two FDA rejections in 2010.
The injectable 5-HT3 receptor antagonist uses Heron’s polymer-based delivery tech to maintain efficacy for five or more days for patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.